Company news

Biomea Fusion, Inc. news in 2025

Biomea Fusion, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Biomea Fusion to Present at the 44th Annual J.P. Morgan Healthcare Conference

December 17, 2025

Biomea Fusion Announces KOL Presentation and Interview on Menin and Icovamenib at WCIRDC 2025

December 9, 2025

Biomea Fusion Presents COVALENT-111 Study Results at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)

December 5, 2025

Biomea Fusion Announces Oral Presentation of Icovamenib at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)

December 1, 2025

Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

December 1, 2025

Biomea Fusion to Participate at Upcoming Investor Conferences

November 24, 2025

Biomea Fusion to Participate at Jefferies London Healthcare Conference

November 10, 2025

Biomea Fusion Showcases Preclinical Advances for BMF-650 and Icovamenib with Low Dose Semaglutide at ObesityWeek® 2025

November 5, 2025

Biomea Fusion Reports Third Quarter 2025 Financial Results and Corporate Highlights

November 4, 2025

Biomea Fusion to Present Poster Presentations at ObesityWeek®2025

October 30, 2025

Biomea Fusion Announces First Patient Dosed in Phase I Study of BMF-650 a Next-Generation Oral GLP-1 Receptor Agonist

October 27, 2025

Biomea Fusion to Participate in Citi's SMID Biotech C-Suite Fireside Chat Series

October 21, 2025

Biomea Fusion Announces Pricing of Public Offering of Securities

October 7, 2025

Biomea Fusion Announces Proposed Public Offering of Securities

October 6, 2025

Biomea Fusion Announces Positive 52-Week Results from Phase II COVALENT-111 Study in Type 2 Diabetes Demonstrating Non-Chronic Treatment with Icovamenib Benefits Two Distinct Patient Populations

October 6, 2025

Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

September 30, 2025

Biomea Fusion Presents Data Demonstrating Enhanced Preclinical Activity of Icovamenib in Combination with Semaglutide in Type 2 Diabetes (T2D) Animal Model at the 61st EASD Annual Meeting and Provides Additional Corporate Update

September 16, 2025

Biomea Fusion Reports Second Quarter 2025 Financial Results and Corporate Highlights

August 5, 2025

Biomea Fusion Appoints Julianne Averill to its Board of Directors

July 24, 2025

Biomea Fusion Presents New Preclinical and Clinical Data on Icovamenib at the 85th Scientific Sessions of the American Diabetes Association (ADA)

June 23, 2025

Biomea Fusion Reports Preclinical Data for BMF-650, a Next-Generation Oral GLP-1 Receptor Agonist Candidate, Demonstrating Robust Weight Loss and Appetite Suppression in Obese Non-Human Primates

June 18, 2025

Biomea Fusion Presents Updated Preliminary Clinical Data for Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia at EHA 2025

June 13, 2025

Biomea Fusion’s BMF-500 Selected for Poster Presentation at EHA 2025 Highlighting Phase I Data in Relapsed/Refractory Acute Leukemia

May 14, 2025

Biomea Fusion Reports First Quarter 2025 Financial Results and Corporate Highlights

May 5, 2025

Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

April 1, 2025

Biomea Fusion Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights

March 31, 2025

Biomea Fusion Announces Leadership Transition

March 25, 2025

Icovamenib Treatment in Patients with Severe Insulin-Deficient Diabetes Led to a Significant Improvement in Pancreatic Beta-cell Function with a 53% Mean Increase in C-peptide Levels 3 Months After Last Dose

March 24, 2025

Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

March 2, 2025

Biomea Fusion to Unveil New Icovamenib Data at the 18th International Conference on Advanced Technologies & Treatments for Diabetes

February 27, 2025

Biomea Fusion Reports New Preclinical Data on Icovamenib-Semaglutide Combination Study

January 6, 2025

Decks in 2025